Verge Genomics
Discovers therapeutics for neurodegenerative diseases utilizing human genomic data.
What they do
Verge Genomics uses human genomic data and an all-in-human translation platform to discover therapies for diseases like ALS and Parkinson's. Their technology bypasses traditional animal models by testing compound efficacy directly on patient-derived tissues, streamlining discovery for pharmaceutical partners.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- South San Francisco, USA
- Region
- North America
- Founded
- 2015
- Total funding
- $134M raised
Notable investors: BlackRock, Eli Lilly, Mercer Street, ALS Investment Fund.